New US Lung Imaging Guidelines Name Technegas as Preferred A
Filed with ASX · · 2 pages · English
Summary by 6ix AI
The guidelines, published by four leading nuclear medicine societies, specifically recognize Technegas and call for a shift to three-dimensional scanning techniques. This recognition is expected to enhance the adoption and utilization of Technegas across US hospitals and health systems. The guidelines also highlight the advantages of Technegas in terms of radiation dose compared to traditional imaging methods.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
In the deck
Earlier from Cyclopharm
- Immediate 11-Site Technegas Rollout at University Hospitals
- CYC First-Half 2026 Update
- USA Technegas Expansion Update
- CYC Secures Multi-Site Agreement with Northwestern Medicine
- CYC Signs Enterprise Agreement with UPHS
Later from Cyclopharm
- CYC 1H2026 Results Summary
- Chinese Consensus Names Technegas Preferred Lung Agent
- Cyclopharm Q3 2026 Update
Follow Cyclopharm into a list and get an email when it puts out news.
Follow Cyclopharm